GENFIT S A/ADR (NASDAQ:GNFT) had its price objective cut by HC Wainwright to $72.00 in a report published on Monday, The Fly reports. They currently have a buy rating on the stock.
Separately, Barclays initiated coverage on GENFIT S A/ADR in a research note on Monday. They issued an overweight rating and a $55.00 price target on the stock.
Shares of GNFT stock opened at $25.60 on Monday. GENFIT S A/ADR has a one year low of $20.81 and a one year high of $26.25.
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Read More: Bond
Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.